Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: Double-blind study

British Journal of Psychiatry

Volumn 194, Issue 2, 2009, Pages 158-164

  Haas, Magali ^a,c   Eerdekens, Mariëlle ^a   Kushner, Stuart ^b   Singer, Julia ^b   Augustyns, Use ^a   Quiroz, Jorge ^b   Pandina, Gahan ^b   Kusumakar, Vivek ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c NONE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIPARKINSON AGENT; ASPARTATE AMINOTRANSFERASE; DIAZEPAM; HYDROXYZINE; LORAZEPAM; RISPERIDONE; ZOLPIDEM; ZOPICLONE;

ADOLESCENT; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOMUTILATION; BODY WEIGHT; BRAIN EDEMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ELECTROCARDIOGRAM; ELECTROENCEPHALOGRAM; EMOTIONAL DISORDER; FEMALE; GALACTORRHEA; GENERAL CONDITION IMPROVEMENT; GYNECOMASTIA; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; HYPERTENSION; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MUSCLE HYPERTONIA; MUSCLE SPASM; OCULOGYRIC CRISIS; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; PSYCHOEDUCATION; PSYCHOSIS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TACHYCARDIA; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

ACUTE DISEASE; ADOLESCENT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 60149093395     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.107.046177     Document Type: Article

References (34)

1. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
2. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 2005; 10: 434-49.
3. Homburger A. vorlesungen uber Psychopathologie des Kindersalters. Springer; 1926.
4. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001; 40 (suppl): S4-23.
5. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington j, walker E, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28-37.
6. Schimmelman B, Conus P, Cotton S, McGorry P, Lambert M. Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 2007; 95: 1-8.
7. Harris M, Henry L, Harrigan S. The relationship between the duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005; 79: 85-93.
8. Pencer A, Addington j, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatry Res 2005; 133: 35-43.
9. Ballageer T, Malia A, Manchanda R, Takhar J, Haricharan R. Is adolescent- onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 2005; 44: 782-9.
10. Remschmidt H, Schulz E, Martin M, Warnke A, Trott GE. Childhood-onset schizophrenia: history of the concept and recent studies. Schizophr Bull 1994; 20: 727-45.
11. Armenteros J. Risperidone in adolescents with schizophrenia: an open-label study. J Am Acad Child Adolesc Psychiatry 1997; 36: 694-700.
12. Balderssarini RJ, Teicher MH. Dosing of antipsychotic agents in pediatric populations. J Child Adolesc Psychopharmacol 1995; 5: 1-4.
13. Quintana, H., Keshavan, M. Risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 1995; 34: 1292-6.
14. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151; 825-35.
15. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients. J Clin Psychopharmacol 1993; 13: 25-40.
16. Schooler n, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947-53.
17. Aman MG, De Smedt G, Derivan A, Findling RL, Group RDBS. Double-blind, placebo-controlled study of risperidone in the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159, 1337-46.
18. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens; M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J psychiatry 2006; 163: 402-10.
19. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006; 16: 260-72.
20. Mccracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002; 347: 314-21
21. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
22. American Psychiatric Association. Handbook of Psychiatric Measures. APA, 2000.
23. Rosner B, Prineas R. Loggie J, Daniels SR. Percentiles for body mass index in US children 5 to 17 years of age. J Pediatr 1998; 132: 211-22.
24. Lindenmayer SR. A new five factor model of schizophrenia Psychiatric O 1994; 65: 299-322.
25. Guy W (ed). Clinical Global Impression (CGI). In ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare, 1976.
26. Uppsala Monitoring Centre The WHO Adverse Reaction Database. World Health Organization. 2004.
27. Guy W (ed). AIMS. Abnormal Involuntary Movement Scale. In ECDEU Assessment Manual for Psychopharmacology: 534-7. US Department of Health, Education and Welfare, 1976.
28. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672-6.
29. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-9.
30. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29: S43-8.
31. Dittmann R, Meyer E, Freisleder F. Effeciveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008; 18: 54-69.
32. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538-46.
33. Pandina G, Aman MG, Findling RL. Risperidone in the management of disruptive behavior disorders. J Child Adolesc Psychopharmacol 2006; 16: 379-92.
34. Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzipine. J Child Adolesc Psychopharmacol 2002; 12: 83-91.